91Ó°ÊÓ

When someone, such as a healthcare worker, potentially comes into contact with HIV, immediate action is crucial. HIV post-exposure prophylaxis (PEP) is a treatment started soon after a possible exposure to the virus, aiming to prevent seroconversion and infection. PEP must be initiated as soon as possible, optimally within a few hours, but certainly not beyond 72 hours after exposure.
PEP is typically prescribed for a duration of 28 days. The main goal is to stop the virus from taking hold in the body and to protect the individual from developing HIV. Successful PEP hinges not only on timely administration but also on strict adherence to the full course of medication prescribed.
Understanding the urgency and importance of PEP helps those at risk take informed decisions quickly, emphasizing the significance of rapid response and adherence to medication.

Nucleoside Reverse Transcriptase Inhibitors (NRTIs) play a foundational role in antiretroviral therapy, including post-exposure prophylaxis. NRTIs function by targeting a crucial enzyme in the HIV lifecycle - reverse transcriptase. This enzyme is vital for the virus as it helps in converting its RNA into DNA, which is necessary for successful integration into the host's cells.
By effectively blocking this process, NRTIs prevent HIV from replicating within the body. Common drugs in this category include Tenofovir, Zidovudine, and Emtricitabine. These medications are chosen for their effectiveness and established safety profile in PEP regimens.
The inclusion of NRTIs in PEP regimens emphasizes their integral role in halting HIV replication early in its lifecycle, making them a key component in both viral suppression and prevention.

Protease Inhibitors (PIs) are another class of drugs utilized in HIV treatment and prevention. They work by disrupting the HIV protease enzyme, which is crucial in the final stages of viral replication, specifically in the maturation of virus particles. Without functional protease enzymes, the new viral particles remain non-infectious.
Some of the well-known PIs include Saquinavir, Ritonavir, and Lopinavir. PIs boost the effectiveness of HIV treatments by providing an additional blockade against the virus's lifecycle. In the context of PEP, PIs are sometimes chosen alongside NRTIs to create a robust defense against the infection.
While not always the first-line choice due to complexities in administration and side effects, PIs represent a critical option in comprehensive HIV prophylactic strategies.

Integrase Strand Transfer Inhibitors (INSTIs) represent a modern and effective category of antiretrovirals. By targeting the integrase enzyme, these inhibitors prevent the integration of viral DNA into the host cell's genome, effectively halting replication and spread within the host.
INSTIs are prized for their potency and relatively favorable side effect profile. Drugs like Raltegravir and Dolutegravir belong to this class and are frequently used in both HIV treatment and PEP regimens.
As a component of PEP, INSTIs offer a formidable defense by inhibiting a critical step in HIV replication. Their role is essential in newer, optimized prophylaxis strategies, providing an additional layer of prevention by cutting off the possibility of viral genome integration, thus keeping the host cells uninfected.
Overall, the inclusion of INSTIs in HIV prevention efforts underscores their significance in cutting-edge antiretroviral therapies.